TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice
J. Clin. Invest. Ana Toro, et al. 116:2717 doi:10.1172/JCI25052 [
Go to this article.]
Figure 4TAT-PNP and nonfused PNP treatment induced development of antibodies to PNP. Three-week-old PNP
–/– mice were injected i.p. twice weekly with 0.5 U/g body wt of TAT-PNP or nonfused PNP (5–8 mice per group). Serum samples, drawn at the indicated time points during 24 weeks of TAT-PNP treatment (squares) or 12 weeks of treatment with nonfused PNP (triangles) were assessed for the presence of antibodies by ELISA. Serum samples were diluted 1:100 and added for 2 hours to plates coated with TAT-PNP or nonfused PNP (5 μg/ml). Following washes, HRP-labeled anti-mouse IgG was added. The assay was developed using TMB substrate. OD was read at 450 nm. Results are mean ± SD.
